Hikma launches Diazepam injection
Diazepam injection is indicated for the management of anxiety disorders as well as for symptoms of acute alcohol withdrawal.
Hikma is offering a Diazepam injection in a 50 mg/10 ml dose.
Diazepam injection is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety as well as symptoms of acute alcohol withdrawal.
It also is a useful adjunct in status epilepticus and may help relax muscles or relieve muscle spasms.
[Read more: Hikma to launch 4 generics in Canada]
Hikma also markets Diazepam in prefilled syringe form.
[Read more: Hikma to acquire Custopharm]
Diazepam injection had a market value of approximately $4 million in the 12 months ending February 2023, per IQVIA.